Home  |   Companies  |   Targets  |   Drugs  |   Diseases  |   Search  |   Help  |   About Blog Blog | Twitter Twitter | Rss SciBite News | Contact Contact   
LogoBeta Software
Open Drug Discovery Intelligence
      
searchSearch Scibite.com

Targets, Diseases & Drug Names All News
a- A+
SCIBITE NEWS:
SciBite version 1.8 is here! Read More On This Release which includes SciBite Central, new visualisations and enhancements to our grant data
 Welcome
 What is SciBite?
 Getting Started Video and General Help
 About Us
 Follow @YouTube, Slideshare, Twitter, Blog
 SciBite Central
 SciBite Central - home to major newsfeeds covering critical drug discovery topics
 Check out our new Kinase portal, providing intelligence on this critical target family
 Favourites   
Loading Favourites....

Please read this important note before using this feature!

 Top News Items

SciBite takes the best of the papers, patents, trials and news items it finds and tweets them as @SciBite to twitter. By highlighting the critical entities in these articles, people are more easily able to find important new information that's relevant to them. Below is a selection of our recent tweets.


More New Articles
Welcome To SciBite: Intelligent Biomedical Alerting
SciBite is a free, drug-discovery focused search engine and alerting service. We index 1000s of papers, patents, blogs, grants, clinical trials and newsfeeds and find the articles that matter for the targets, drugs, diseases and companies you care about, looking right across the drug pipeline. We're not a general purpose text search tool, there are many others that do that. Rather, we provide highly-tailored tracking of critical topics in research and development. See our Help Guide for more info about how SciBite works.

Get Started, Enter A Human Disease, Drug, Company or Target:  

Examples: Asthma , Jantoven, Thrombospondin 1, Pfizer

 Todays Hot Topics
SciBite's unique real-time intelligence service continually scans to identify those topics with the highest news traffic. Click on any item to jump straight to the latest news.